U.S. market Closed. Opens in 2 days 54 minutes

AMAM | Ambrx Biopharma Inc. Stock Financials Income Statements Annual

(Stock Exchange: NYSE)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-31
Revenue7.40M7.46M13.67M10.31M
Cost of RevenueN/AN/AN/AN/A
Gross Profit7.40M7.46M13.67M10.31M
Operating Expenses74.14M71.88M26.79M32.78M
Selling, General & Admin23.05M17.07M6.35M6.40M
Research & Development53.31M54.81M20.43M26.38M
Other Operating Expenses-2.22M-3.86M-4.75M-38.00K
Operating Income-57.08M-64.42M-13.12M-22.47M
Other Expenses / Income-18.98M-3.86M-4.72M157.00K
Before Tax Income-76.06M-68.29M-17.84M-22.32M
Income Tax Expenses1.94M1.00K1.00K-2.00K
Net Income-78.00M-68.29M-17.84M-22.31M
Interest Expenses968.00KN/AN/AN/A
Basic Shares Outstanding38.61M20.45M37.67M37.67M
Diluted Shares Outstanding38.61M20.45M37.67M37.67M
EBITDA-55.79M-62.27M-11.17M-20.42M
EBITDA Margin-753.69%-835.28%-81.72%-198.03%
EBIT-75.09M-68.29M-17.84M-22.32M
EBIT Margin-1,014.47%-915.99%-130.48%-216.42%
Financial Year End2022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙